<DOC>
	<DOCNO>NCT00255359</DOCNO>
	<brief_summary>The study randomize , double blind , placebo control , dose rise study Interferon alpha ( IFN-alpha ) non-responder HCV infect patient HCV patient relapse follow IFN-alpha therapy . Eligible subject must compensate liver disease serum HCV RNA concentration 100,000 IU/mL screening . The study include single dose period evaluation acute toxicity single dose pharmacokinetics consecutive multi-dose period determination longer-term safety , multiple-dose pharmacokinetics antiviral activity . The objective study evaluate safety , tolerability , antiviral activity escalate single multiple dos XTL 2125 patient chronic hepatitis C virus infection ass single- multiple-dose pharmacokinetics XTL 2125</brief_summary>
	<brief_title>Safety , Tolerability Efficacy XTL 2125 HCV-Infected Patients Who Are Interferon-Alpha Non-Responders Relapsers</brief_title>
	<detailed_description>The study randomize , double blind , placebo control , multicenter design sequential ascending dos XTL 2125 HCV-infected patient compensate liver disease respond IFN-alpha therapy relapse follow therapy . This study include single dose session multiple dose session . In single dose session , patient randomize receive single oral dose either XTL 2125 placebo Day 1 , dose-escalating design , follow multiple dose session start day 8 continue 14 day . The patient receive XTL 2125 three time daily dose administer single dose session . The following dos administer group 8 patient : 10 mg , 25 mg , 50 mg , 150 mg , 300 mg 450 mg . Within group , 6 subject receive XTL 2125 2 subject receive placebo . No patient enrol one dose level . Doses administered one hour meal 240 cc water . Additional patient may enrol previous intermediate dos obtain additional safety pharmacokinetic/pharmacodynamic data accurately define Maximum Tolerated Dose ( MTD ) . The MTD define last dose level successfully administer decision escalate next level . If decision escalate next level make cohort receives XTL 2125 dose half-way last tolerate dose non-tolerated dose may enrol discretion Sponsor . If dose successfully administer without violate dose escalation rule , interim dose consider MTD . Six dose cohort prospectively indicate , although additional cohort may schedule intermediate dos warrant data .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients must understand willing give write informed consent prior study procedure evaluation willing adhere study schedule requirement . Adults 18 70 year age . Documented history positive HCV serology . Compensated liver disease define follow screening : PT great equal 60 % , INR &lt; 1.5 , serum albumin great equal 3.4 g % , serum bilirubin &lt; 2 mg % ( unless dx Gilbert 's Syndrome ) . Serum HCV RNA great equal 100,000 IU/mL screening . Patients treat respond IFNalpha therapy withdraw therapy within 30 day prior screen . Patients complete fully prescribed course approve IFN alpha base treatment relapse follow end treatment . Patients must sterile infertile use approve method contraception time first dose study medication take three month follow study completion discontinuation . Screening labs follow : platelet count great equal 120,000/mm3 ; ANC great equal 1000/mm3 ; hemoglobin great equal 11.0 g/dL female great equal 12.0 g/dL male ; serum ALT within normal limit &lt; 5 x ULN . Alpha fetoprotein &lt; 25 microg/L screening . Any history significant cardiac , renal , neurologic , metabolic , pulmonary , gastrointestinal , hematologic abnormality , chronic hepatic disease hepatitis C disease judgment investigator would interfere study confound result . Patients positive HIV serology positive HBsAg screening . Patients treat previously current approve therapy HCV . Patients receive previous treatment HCV infection approve regimen IFN alpha ribavirin within 30 day prior screen . Patients decompensated liver disease evidence advance liver disease presence ascites , bleed varix hepatic encephalopathy . Female patient breastfeed positive pregnancy test screening time study . History alcohol drug abuse within 6 month screen . Patients positive urine drug screen substance abuse ( benzodiazepine , THC , opiates , amphetamine , cocaine ) screening . Patients poor venous access History evidence hepatocellular carcinoma ( HCC ) . Use prescription nonprescription drug know metabolize liver potentially interfere study medication ( Marcolide antibiotic , azole antifungal , warfarin , carbamazepine , cyclosporine , midazolam , phenytoin , valporic acid , chlorpromazine , rifampin , quinidine , diazepam digoxin ) 90 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>